Encouraging preclinical results with PSMA-targeting 212Pb-NG001 show lower kidney uptake than 212Pb-labelled PSMA-617 in addition to good tumour uptake and inhibited tumour growth [25, 26], and a clinical trial is being planned. This evidence concerns the gene FOLH1 and neoplasm.